ANG Lifesciences India Limited

BSE: ANG540694ISIN INE236W01016

Healthcare
Pharmaceuticals

Share price

₹37.26+1.32 (+3.67%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹49.69
52W low: ₹17.63
Off 52W high: -25.02%
1M return: -5.38%
3M return: +11.22%
6M return: +31.06%
1Y return: +22.69%
20D avg volume: 3,054
50 DMA: ₹35.31
200 DMA: ₹29.91

Key ratios Consolidated

Market cap: ₹48.66 Cr
Current price: ₹37.26
52W high / low: ₹49.69 / ₹17.63
Face value: ₹10.00
P/E: -3.55
P/B: 0.92
EPS (TTM): ₹-10.20
Book value / share: ₹40.50
ROE: —
ROCE: -8.50%
Operating margin: —
Net margin: —
Debt / equity: 1.47
Net debt: ₹77.04 Cr
Interest cover: -0.64
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 242.4 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	15.30	23.50	18.73	26.05	24.60	16.82	24.73	32.88	18.41	—
	0.11	0.17	0.16	0.12	0.09	0.65	0.27	0.35	1.28	—
	15.41	23.67	18.89	26.18	24.69	17.47	24.46	33.23	19.70	—
	20.98	24.78	24.86	29.39	27.42	21.36	30.84	34.52	23.84	—
	9.65	12.49	10.37	18.05	16.43	10.62	16.91	24.13	12.24	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	3.93	3.59	4.26	4.32	4.36	4.17	4.44	4.58	4.26	—
	2.24	2.18	1.93	1.89	1.94	2.42	2.00	2.18	2.08	—
	1.50	1.77	1.51	1.52	1.53	1.42	1.97	1.74	1.63	—
	2.90	3.72	4.20	3.81	3.37	2.90	6.38	4.57	4.19	—
	-5.58	-1.10	-5.96	-3.21	-2.73	-3.89	-6.38	-1.29	-4.14	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	-5.58	-1.10	-5.96	-3.21	-2.73	-3.89	-6.38	-1.29	-4.14	—
	-1.34	0.28	-1.21	-0.27	-0.73	-1.83	1.19	0.80	1.07	—
	-4.24	-1.38	-4.75	-2.95	-2.01	-2.06	-5.19	-2.09	-3.07	—
	-3.24	-1.07	-3.60	-2.24	-1.52	-1.56	-3.98	-1.53	-2.35	—
Key metrics
	-1.84	2.85	-2.52	0.20	0.74	-0.05	-2.41	2.63	-0.43	—
	-12.00%	12.10%	-13.50%	0.80%	3.00%	-0.30%	-9.70%	8.00%	-2.30%	—
	-27.70%	-5.90%	-25.40%	-11.30%	-8.20%	-12.20%	-21.00%	-6.40%	-16.70%	—
	—	1.80%	—	-1.80%	—	-1.70%	—	—	—	—
	-37.80%	39.70%	-24.30%	-20.80%	33.60%	—	—	—	—	—
	-110.90%	33.00%	8.50%	-41.10%	34.50%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	83.58	92.89	92.85	—
	0.56	0.54	2.01	—
	84.15	93.44	94.86	—
	100.01	106.45	110.56	—
	50.56	57.34	63.90	—
	0.00	0.00	0.00	—
	16.10	16.54	17.45	—
	8.24	7.93	8.69	—
	6.30	6.33	6.76	—
	14.63	15.11	18.04	—
	-15.85	-13.01	-15.70	—
	0.00	0.00	0.00	—
	-15.85	-13.01	-15.70	—
	-2.54	-1.93	3.29	—
	-13.32	-11.09	-12.41	—
	-10.15	-8.43	-9.42	—
Key metrics
	-1.31	1.25	-0.25	—
	-1.57%	1.30%	-0.30%	—
	-15.94%	-11.90%	-13.40%	—
	—	-8.50%	-8.10%	—
	-15.60%	0.00%	—	—
	—	10.60%	—	—
	—	10.59	-4.01	—
	—	-0.99	0.02	—
	—	1.47	1.26	—
	—	77.04	80.27	—
	—	242.4	214.6	—
Balance sheet
	—	208.95	229.59	—
	—	145.12	161.03	—
	—	0.49	0.16	—
	—	67.93	66.54	—
	—	46.26	54.11	—
	—	22.94	27.11	—
	—	50.61	57.19	—
	—	52.51	66.07	—
	—	149.04	143.44	—
	—	77.53	80.43	—
	—	72.91	61.57	—
	—	4.62	18.86	—
	—	52.89	63.98	—
Cash flow
	—	11.03	-0.26	—
	—	1.05	-1.59	—
	—	-11.74	1.68	—
	—	0.44	3.75	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	13.96	22.80	18.30	25.97	24.53	17.67	23.91	32.16	16.18	—
	0.19	0.19	0.16	0.21	0.17	0.75	0.03	0.36	1.36	—
	14.15	22.99	18.46	26.18	24.71	18.42	23.88	32.52	17.54	—
	18.66	21.56	23.44	26.80	25.73	21.38	29.44	33.19	21.28	—
	8.57	11.00	10.61	17.01	16.45	11.57	16.85	24.18	11.37	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	3.47	3.32	3.67	3.86	3.49	3.44	3.72	3.79	3.50	—
	1.77	1.65	1.61	1.59	1.61	2.05	1.71	1.87	1.67	—
	1.47	1.73	1.45	1.45	1.45	1.30	1.84	1.62	1.51	—
	2.60	1.92	4.00	3.45	2.99	2.76	6.03	4.15	3.74	—
	-4.51	1.43	-4.98	-0.62	-1.03	-2.96	-5.56	-0.67	-3.75	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	-4.51	1.43	-4.98	-0.62	-1.03	-2.96	-5.56	-0.67	-3.75	—
	-1.09	0.33	-0.74	0.18	0.24	-1.02	1.00	0.41	0.98	—
	-3.42	1.10	-4.24	-0.80	-0.79	-1.94	-4.57	-1.07	-2.77	—
	-2.59	0.90	-3.23	-0.60	-0.59	-1.50	-3.50	-0.75	-2.12	—
Key metrics
	-1.27	4.81	-1.92	2.42	2.03	0.39	-2.01	2.82	-0.57	—
	-9.10%	21.10%	-10.50%	9.30%	8.30%	2.20%	-8.40%	8.80%	-3.50%	—
	-24.50%	4.80%	-23.20%	-3.10%	-3.20%	-11.00%	-19.10%	-3.30%	-17.10%	—
	—	4.70%	—	1.40%	—	-1.10%	—	—	—	—
	-43.10%	29.00%	-23.50%	-19.20%	51.60%	—	—	—	—	—
	-332.90%	156.70%	7.20%	25.20%	71.50%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	81.03	91.61	89.91	—
	0.75	0.73	2.44	—
	81.78	92.33	92.35	—
	90.46	97.52	105.29	—
	47.19	55.08	63.98	—
	0.00	0.00	0.00	—
	14.32	14.35	14.45	—
	6.62	6.45	7.30	—
	6.10	6.08	6.27	—
	11.97	12.36	16.68	—
	-8.68	-5.19	-12.94	—
	0.00	0.00	0.00	—
	-8.68	-5.19	-12.94	—
	-1.32	0.47	2.60	—
	-7.36	-4.73	-10.34	—
	-5.52	-3.52	-7.86	—
Key metrics
	4.04	7.34	0.63	—
	4.99%	8.00%	0.70%	—
	-9.08%	-5.20%	-11.50%	—
	—	1.90%	-6.80%	—
	-17.54%	1.90%	—	—
	—	54.30%	—	—
	—	9.59	-6.41	—
	—	-2.90	0.22	—
	—	1.04	1.01	—
	—	64.69	67.73	—
	—	232.6	192.3	—
Balance sheet
	—	189.91	208.67	—
	—	132.97	146.57	—
	—	0.28	0.08	—
	—	65.35	64.96	—
	—	33.00	37.84	—
	—	26.89	30.58	—
	—	47.05	52.63	—
	—	39.99	55.42	—
	—	124.58	125.37	—
	—	64.97	67.81	—
	—	64.13	54.47	—
	—	0.84	13.34	—
	—	62.22	66.81	—
Cash flow
	—	13.72	-2.29	—
	—	-3.33	-1.63	—
	—	-10.19	3.92	—
	—	4.13	4.12	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -17.54%
Profit YoY (TTM): +12.07%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -15.60%
Profit YoY (TTM): -17.36%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 70.60%

Quarter	September 2026	June 2026
Promoter %	70.60%	70.60%

Holder	Type	Holding	Previous	Change
Rajesh Gupta	Promoter	70.41%	70.41%	0.00%
Saruchi Gupta	Promoter	0.19%	0.19%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
ANG Lifesciences India Limited	49	37.26	-3.55	-8.50%	-15.60% TTM	-17.36% TTM	+22.69%

Filings & corporate actions

Recent announcements

Disclosure under Reg 74(5) of SEBI (DP) Regulations,201816 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Scrutinizer''s Report for AGM along with Voting Results1 Oct 2026 · AGM/EGM / AGM
Re-appointment of Ms. Chetna as the Independent Director of the company.30 Sep 2026 · Company Update / Change in Management
Proceedings of 20th Annual General Meeting are enclosed herewith.30 Sep 2026 · AGM/EGM / AGM
Intimation of Closure of Trading Window.23 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to Regulations 30 and 34 of the SEBI (LODR) Regulations, 2015, as amended ('''' Listing Regulations''''), please find attached herewith the Annual Report of the Company for the ....7 Sep 2026 · Others / Reg. 34 (1) Annual Report
Notice of 20th AGM7 Sep 2026 · AGM/EGM / AGM
Intimation of Book Closure7 Sep 2026 · Corp. Action / Book Closure
Intimation of 20th Annual General Meeting7 Sep 2026 · AGM/EGM / AGM
This is to inform you, pursuant to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Board of Directors ....7 Sep 2026 · Others / Outcome without intimation
Financial Results 30.06.2026.14 Aug 2026 · Result / Financial Results
Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 201514 Aug 2026 · Board Meeting / Outcome of Board Meeting
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Standalone and Consolidated ....7 Aug 2026 · Board Meeting / Board Meeting
Reg 74(5) Certificate21 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window19 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Publication of Audited Financial Results for the quarter and year ended March 31, 2026.5 Jun 2026 · Company Update / Newspaper Publication
Audited Results 31.03.202630 May 2026 · Result / Financial Results
Audited Financial Results for the quarter and year ended 31st March, 202630 May 2026 · Board Meeting / Outcome of Board Meeting
Annual Secretarial Compliance Report 31.03.2026.29 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Standalone & Consolidated ....22 May 2026 · Board Meeting / Board Meeting
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....17 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Certificate under Reg 74(5) of SEBI (DP) Regulations, 201815 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is with reference to the email communication received from BSE Limited on April 09,2026 seeking clarification for a significant movement in the price of the securities of the company.10 Apr 2026 · Company Update / General
The Exchange has sought clarification from ANG Lifesciences India Ltd on April 9, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....10 Apr 2026 · Company Update / Clarification
Intimation of closure of Trading Window.25 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Unaudited Financial Results 31.12.2025.14 Feb 2026 · Result / Financial Results
Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-202514 Feb 2026 · Board Meeting / Outcome of Board Meeting
Revised Annual Secretarial Report for the year ended 31.03.2025.6 Feb 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve the Unaudited Standalone ....5 Feb 2026 · Board Meeting / Board Meeting
Disclosure under Reg. 74(5) of SEBI (DP), Regulations, 2018.22 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window.22 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
Unaudited Financial Results for the Quarter and Half year ended 30.09.2025.14 Nov 2025 · Result / Financial Results
Considered and approved the financial results for the quarter and half year ended 30th September 202514 Nov 2025 · Board Meeting / Outcome of Board Meeting
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Pursuant to the Regulation ....6 Nov 2025 · Board Meeting / Board Meeting
Certificate under Reg 74(5) of SEBI (DP) Regulations, 201815 Oct 2025 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Scrutinizer''s Report along with voting Results1 Oct 2025 · AGM/EGM / AGM
Appointment of Secretarial Auditor30 Sep 2025 · Company Update / General
Proceedings of the 19th AGM of the company are enclosed herewith.30 Sep 2025 · AGM/EGM / AGM
Closure of Trading Window24 Sep 2025 · Insider Trading / SAST / Closure of Trading Window
Clarification on Price Movement12 Sep 2025 · Company Update / General

Board meetings

14 Aug 2026 Board Meeting - Financial Results